Changing the Lives of Patients with Myotubular and Centronuclear Myopathies (CNM).
Location: France, Grand Est, Illkirch-Graffenstaden
Employees: 11-50
Total raised: $110.24M
Founded date: 2016
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.04.2020 | Series C | $55M | - |
| 06.07.2018 | Series A | $55.24M | - |
Mentions in press and media 16
| Date | Title | Description |
| 18.11.2024 | ExeVir Announces Michael Garrett as New CEO | ExeVir Bio, a Ghent, Belgium-based biotech company developing heavy chain-only antibodies targeting highly conserved epitopes for broad protection against infectious diseases, announced the appointment of Michael Garrett as its new Chief Ex... |
| 17.06.2023 | Flamingo Therapeutics Receives €1.7M Grant Award from VLAIO | Flamingo Therapeutics, a Leuven, Belgium-based company pioneering RNA-targeted therapies for oncology, has been awarded a research grant of €1.7 million by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding... |
| 09.06.2021 | Dynacure Announces FDA Acceptance of Investigational New Drug Application for DYN101 for Myotubular and Centronuclear Myopathies | |
| 26.02.2021 | Dynacure Recognizes Rare Disease Day 2021 | |
| 26.01.2021 | Dynacure Announces Issuance of U.S. Patent for DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM) | |
| 21.01.2021 | Dynacure Announces Appointment of Jean M. Franchi to its Board of Directors | |
| 15.01.2021 | Dynacure announces publication of Hierarchical Bayesian modelling of disease progression in Orphanet Journal of Rare Diseases | |
| 02.04.2020 | Dynacure Announces €50M ($55M) Series C Financing | STRASBOURG/PHILADELPHIA, April 2, 2020 – Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today the close of a €50 million Series C financing led by Per... |
| 02.04.2020 | Dynacure Raises €50M in Series C Financing | Dynacure, a Strasbourg, France-based clinical stage drug development company focused on rare and orphan disorders, closed a €50m Series C financing. The round was led by Perceptive Advisors, with participation from new investors Bpifrance L... |
| 02.04.2020 | Dynacure Closes $55M Series C Financing | Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today the close of a €50 million Series C financing led by Perceptive Advisors. New investors participa... |
Show more